Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Among authors: usnarska zubkiewicz l. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: usnarska zubkiewicz l. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.
Charliński G, Grząśko N, Bołkun Ł, Sawicki W, Paczkowska E, Druzd-Sitek A, Usnarska-Zubkiewicz L, Butrym A, Wiater E, Boguradzki P, Budziszewska B, Wojciechowska M, Mordak-Domagała M, Jurczyszyn A. Charliński G, et al. Among authors: usnarska zubkiewicz l. J Oncol Pharm Pract. 2024 Oct;30(7):1144-1151. doi: 10.1177/10781552231203371. Epub 2023 Sep 20. J Oncol Pharm Pract. 2024. PMID: 37728209
Prognostic factors and clinical characteristics of patients with newly diagnosed non-secretory multiple myeloma in the era of new drugs in "real-world" study: Experiences of the Polish Myeloma Group.
Charliński G, Szudy-Szczyrek A, Podgajna M, Mielnik M, Kopińska A, Tyczyńska A, Usnarska-Zubkiewicz L, Bołkun Ł, Wiater E, Krzystański M, Vesole DH, Jurczyszyn A. Charliński G, et al. Among authors: usnarska zubkiewicz l. Adv Clin Exp Med. 2024 Aug 29. doi: 10.17219/acem/189390. Online ahead of print. Adv Clin Exp Med. 2024. PMID: 39206811
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Avivi I, Vesole DH, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, Baumert B, Osękowska B, Kopińska A, Gentile M, Puertas-Martinez B, Robak P, Crusoe E, Rodriguez-Lobato LG, Gajewska M, Varga G, Delforge M, Cohen Y, Gozzetti A, Pena C, Shustik C, Mikala G, Zalac K, Alexander HD, Barth P, Weisel K, Martínez-López J, Waszczuk-Gajda A, Krzystański M, Jurczyszyn A. Avivi I, et al. Among authors: usnarska zubkiewicz l. Cancers (Basel). 2023 Sep 1;15(17):4359. doi: 10.3390/cancers15174359. Cancers (Basel). 2023. PMID: 37686635 Free PMC article.
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.
Charliński G, Steinhardt M, Rasche L, Gonzalez-Calle V, Peña C, Parmar H, Wiśniewska-Piąty K, Dávila Valls J, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Gozzetti A, Ciofini S, Gentile M, Zamagni E, Kurlapski M, Legieć W, Vesole DH, Jurczyszyn A. Charliński G, et al. Among authors: usnarska zubkiewicz l. Cancers (Basel). 2024 Apr 21;16(8):1592. doi: 10.3390/cancers16081592. Cancers (Basel). 2024. PMID: 38672674 Free PMC article.
Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.
Kulikowska de Nałęcz A, Ciszak L, Usnarska-Zubkiewicz L, Pawlak E, Frydecka I, Szmyrka M, Kosmaczewska A. Kulikowska de Nałęcz A, et al. Among authors: usnarska zubkiewicz l. Int J Mol Sci. 2023 Mar 17;24(6):5730. doi: 10.3390/ijms24065730. Int J Mol Sci. 2023. PMID: 36982802 Free PMC article.
The Role of Lifestyle and Environmental Factors in the Pathogenesis of Multiple Myeloma.
Suska A, Tyczyńska A, Zaucha JM, Kopińska A, Helbig G, Markiewicz M, Warzybok K, Leder E, Grosicki S, Machaliński B, Baumert B, Bator M, Usnarska-Zubkiewicz L, Fornagiel S, Ciepłuch H, Waszczuk-Gajda A, Kruczkowska-Tarantowicz K, Rzepecki P, Hus M, Morawska-Krekora A, Raźny M, Charliński G, Puła A, Nita E, Wojciechowska M, Krawczyk-Kuliś M, Goldberg J, Woźny T, Rodzaj M, Olejarz D, Gronau-Dziurkowska M, Skalniak E, Krzysztoń J, Niezabitowska K, Jurczyszyn A. Suska A, et al. Among authors: usnarska zubkiewicz l. Eur J Haematol. 2025 Jan 8. doi: 10.1111/ejh.14356. Online ahead of print. Eur J Haematol. 2025. PMID: 39777794
Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Zaleska J, Kwasnik P, Paziewska M, Purkot J, Szabelak A, Jurek M, Masny N, Dziatkiewicz I, Pronobis-Szczylik B, Piebiak A, Szymczyk A, Jarosz-Chudzik K, Bolkun L, Kozlowska K, Piszcz J, Subocz E, Halka J, Bator M, Kalicinska E, Wrobel T, Usnarska-Zubkiewicz L, Rybka J, Deren-Wagemann I, Szyca-Smieszniak M, Dybko J, Hus I, Pula B, Cichocka E, Rymko M, Zdunczyk D, Ziarkiewicz M, Basak GW, Bullinger L, Giannopoulos K. Zaleska J, et al. Among authors: usnarska zubkiewicz l. Int J Cancer. 2023 Feb 15;152(4):705-712. doi: 10.1002/ijc.34209. Epub 2022 Jul 27. Int J Cancer. 2023. PMID: 35830214 Free PMC article.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
86 results